Scholar Rock Holding Corp. (SRRK)

Scholar Rock's stock price has been impacted by several events over the past six months. The stock saw a significant gain after reporting its Q3 2025 earnings. The stock price increased between February 3, 2025, and January 30, 2026. Analysts have shown a bullish sentiment. Citigroup and UBS initiated coverage of SRRK with "Buy" recommendations. Barclays and JP Morgan maintained "Overweight" recommendations. Wolfe Research also initiated coverage with an "Outperform" recommendation. There has been notable insider selling activity, but some insider buying was also reported. SRRK options indicated a bearish sentiment in the market. The stock currently holds "buy" signals from both short and long-term Moving Averages.

Seasonality might be a factor for SRRK, as financial platforms track and display mean and median monthly returns to identify seasonal patterns for the stock. Specific details regarding the demand seasonality for Scholar Rock Holding Corp.'s products and services are not provided.

Scholar Rock Holding Corp. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases related to protein growth factor signaling. The company develops monoclonal antibodies that selectively target precursor proteins before activation. Its major product candidates include Apitegromab, SRK-181, SRK-015 and BMP6. The company is also developing a pipeline of product candidates for neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.

Scholar Rock Holding Corp. is headquartered in Cambridge, Massachusetts, United States.

Scholar Rock's brand reputation over the past year appears to be largely positive within the financial and biotech communities, primarily driven by strong analyst recommendations. The company has received a consensus "Buy" rating from analysts. While there have been reports of significant insider selling, there is no explicit mention of events that have broadly damaged the company's public or brand reputation.

Scholar Rock Holding Corp. has a significant institutional ownership base, with 475 institutional owners and shareholders holding a total of 130,004,773 shares. Major institutional owners include Fmr Llc, Siren, L.L.C., Price T Rowe Associates Inc /md/, BlackRock, Inc., Samsara BioCapital, LLC, Vanguard Group Inc, Wellington Management Group Llp, Redmile Group, LLC, State Street Corp, PRNHX - T. Rowe Price New Horizons Fund, Inc., Invus Public Equities, L.P., Artal Group S.A., Jennison Associates LLC, Pictet Asset Management Holding SA, and UBS Group AG. Srinivas Akkaraju is the largest individual shareholder, and several company officers have been involved in recent stock transactions.